An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.

Cancer Clinical Trial

— Hercules  

Official title:

A Multi-Site Prospective, Single-Arm, Observational Study On The Accuracy Of Whole Body Magnetic Resonance Imaging (Wb-Mri) Screening To Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06212479
• Other study ID #: MA- 001
• Status: Recruiting
• Start date: May 17, 2024
• Est. completion date: January 2037

Study information

• Verified date: May 2024
• Source: Hercules
• Contact: Pratik Shingru, MD, MPH
• Phone: 8337736886
• Email: pratik.shingru[@]herculesstudy.org.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion/exclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: January 2037
• Est. primary completion date: January 2034
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Each subject MUST:
• Be>=18 years of age at the time of enrollment.
• Be able to read and understand provided procedural information for the study;
• Be able and willing to follow all study procedures including proper breathing and body movement minimization while within the WB-MRI system;
• Be willing and able to provide required clinical, demographic, medical history, and concomitant medications information;
• Be able to provide financial payment in advance for reimbursement of the cost of the WBMRI acquisition procedure and interpretation;
• Complete all required consent procedures.

Exclusion Criteria:

• Harbor within their bodies contraindicated medical devices including, but not limited to, implanted pacemakers, intracranial aneurysm clips, cochlear implants, drug infusion pumps, neurostimulators, bone growth stimulators, certain intrauterine contraceptive devices, non- MRI safe metals, etc.;
• Self-certify that they are pregnant;
• Be seeking to undergo WB-MRI as a subject in this study in lieu of other covered dedicated diagnostic imaging evaluations when such covered procedures represent more appropriate or standard-of-care procedures by context-specific clinical indication;
• Be an employee of the study site or the sponsor;
• Have a medical condition or serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the candidate's safety as a study subject, or that could interfere with study objectives.

Related Conditions & MeSH terms

• Aneurysm
• Cancer
• Metabolic Disease
• Metabolic Diseases
• Nervous System Diseases
• Neurologic Disorder

Intervention

Diagnostic Test:
• MRI Scan
Whole Body MRI Scan

Locations

Country	Name	City	State
United States	Hercules Research Center	Watertown	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Hercules	Prenuvo Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint and 5-point scale of CSD (Clinically Significant Disease) of CSD diagnosed post-baseline in general population subjects.	Clinically significant disease represents the primary output of WB-MRI image analysis, and thus, the primary endpoint for this study. This outcome will be expressed as a 5-point scale similar to the standard Likert scale used in clinical studies. Higher the number higher the risk of clinically significant finding.	Up to 10 Years
Secondary	Secondary Endpoint of ONCO-RADS Score (Oncological relevant findings reporting and data system) diagnosed in the follow-up period, including but not limited to, types of cancers, aneurysms, metabolic disorders, neurologic disorders, renal function, etc	Additionally, for the purposes of more specifically distinguishing CSD's of oncological-concern, following the ONCO-RADS7 guidelines for cancer screening utilizing WB-MRI, an additional ONCO-RADS score tag ("ONCO") will be attached to each CSD to reflect oncologic-specific risk according to the screening WB-MRI criteria. Higher the number worse the risk of having Cancer.	Up to 10 Years